Zalgen Labs is a biotechnology company founded in 2011, specializing in the design and production of superior biological molecules critical for the development and commercialization of immunotherapeutics, novel vaccines, and reliable, rapid, and affordable diagnostic platforms targeting neglected and underrepresented human viral infectious diseases including Ebola virus (EBOV) and Lassa virus (LASV). Zalgen technology and products strengthen global capabilities in biosafety, biosecurity and readiness for pathogen outbreaks (most importantly viral hemorrhagic fevers) and support medical countermeasure efforts directed to pandemic diseases and major epidemic-prone diseases.
In the past few years we and our collaborative partners achieved significant performance milestones including securing over $140 million in grant funding, developed and launched the first rapid diagnostic test for Lassa fever, developed and launched the first rapid test for Ebola viral disease to secure emergency use authorization from both the US FDA and the WHO, opened state of the art biotechnology facilities in Maryland and Colorado, published 24 scientific papers in peer-reviewed journals, and established the company as a premier provider of diagnostics, research reagents, and product development solutions for high consequence neglected tropical viral diseases.
In 2020, in response to the global SARS CoV-2 pandemic, we quickly broadened our focus and began development a battery of diagnostic tests, the first of which has been submitted to the FDA for emergency use authorization request.
At Zalgen we are dedicated to making a meaningful difference in developing and deploying medical countermeasures against neglected tropical diseases. Since our inception, we and our academic, government, biotechnology industry and healthcare provider partners have made significant strides against Ebola, Lassa and other highly fatal hemorrhagic viral diseases faced in resource limited areas of the world desperate for resources to enhance scientific research and improve patient care.
Our teams have traveled frequently to Sierra Leone, Nigeria and other West African countries, often during disease outbreaks. Working with scientists and healthcare workers, Zalgen has made measurable advances in the science of viral hemorrhagic diseases to improve the lives of these severe at-risk populations, impacted by these diseases and associated mortality rates approaching or exceeding 70%, and even higher in pregnant women and children.
Our goal is to develop and make available the best, most widely trusted and effective diagnostics, vaccines and immunotherapeutics to make a meaningful difference against these endemic and epidemic diseases. With active and broadly disseminated vaccine programs, field deployable rapid diagnostic tests, and availability of affordable and safe immunotherapeutics, celebrations with young survivors will be the norm rather than just the fortunate few who survive these diseases.
(L-R) Dr. Robert Garry, Dr. Jessica Grove (Hartnett), Lassa fever survivor (with permission), and Dr. Luis Branco. Young survivor of severe Lassa fever at Kenema Government Hospital, Eastern Sierra Leone, 2010. The patient, with family permission, helped our team assemble the most comprehensive longitudinal study of a severe Lassa fever infection with positive outcome recorded to date.
Zalgen Labs is a privately held Maryland Limited Liability Corporation. Established by co-founders Dr. Luis Branco and Dr. Robert Garry in 2011, Zalgen has built a team of skilled and experienced scientists focusing on basic science and product development for the improvement of humankind. At Zalgen, we treat our customers, employees and patients who benefit from our products with the highest level of respect and admiration.
Chief Scientific Advisor and Co-Founder
Managing Director and Co-Founder
Director of Diagnostics Development
Zalgen integrates passion for discoveries and advancement in the biological sciences with uncompromising commitment toward fulfilling diagnostic, preventive, and therapeutic solutions for unmet and underrepresented medical needs worldwide, through excellence, nobility, proven execution, and innovation.
Young patient being tested for Lassa fever with ReLASV Antigen Rapid Test. Kenema Government Hospital, Kenema, Sierra Leone. (2009) Photo courtesy L Branco
The Zalgen organization is committed to highly ethical and responsible behavior in all that we do as individuals and as a team. We have in place policies and procedures resulting in consistent quality of our work product and ensuring all members of our staff are treated with the high level of respect they deserve. New employees are selected, trained and expected to commit to this same high level of ethical behavior.
Zalgen Policies and Procedures include: Adherence to the Research Investigators’ Financial Conflict of Interest (“RIFCOI”) regulations. This includes “Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought” (42 CFR Part 50, Subpart F), and “Responsible Prospective Contractors” (45 CFR Part 94).
20271 Goldenrod Lane, Suite 2083
Germantown, MD 20876
Office: (833) 482-8833 ex: 2
International: (301) 720-0330
Fax: (301) 349-1194
12635 E. Montview Blvd, Suite 325
Aurora, CO 80045
Office: (833) 482-8833 ex: 1
International: (301) 720-0330
Fax: (720) 859-4110